Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 4:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 6,703 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Diseases Clear all
Completed Phase 2 Interventional Results available

Study Of Ispinesib In Subjects With Breast Cancer

NCT00089973
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
Ispinesib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
4
States / cities
Jacksonville, Florida • Indianapolis, Indiana • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2018 · Synced Oct 23, 2026, 4:19 PM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer

NCT02648477
View directory record Official record
Conditions
Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Negative, Progesterone Receptor Positive, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Anastrozole, Doxorubicin Hydrochloride, Exemestane, Laboratory Biomarker Analysis, Letrozole, Pembrolizumab
Drug · Other · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
6
States / cities
Corona, California • Duarte, California • Lancaster, California + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Oct 23, 2026, 4:19 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Understanding and Predicting Breast Cancer Events After Treatment

NCT02791581
View directory record Official record
Conditions
Breast Cancer
Interventions
Cardiac MRI
Diagnostic Test
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
403 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2032
U.S. locations
66
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Tampa, Florida + 52 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 23, 2026, 4:19 PM EDT
Completed Phase 1 Interventional

Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors

NCT00413322
View directory record Official record
Conditions
Tumor
Interventions
belinostat, 5-Fluorouracil (5-FU)
Drug
Lead sponsor
Valerio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
Scottsdale, Arizona • Omaha, Nebraska • Portsmouth, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Oct 23, 2026, 4:19 PM EDT
Terminated Phase 2 Interventional Results available

Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapy

NCT00661531
View directory record Official record
Conditions
Breast Cancer, Cancer of the Breast, Neoplasms, Breast
Interventions
Estrace, Anastrozole
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Voorhees Township, New Jersey • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Oct 23, 2026, 4:19 PM EDT
Completed No phase listed Observational

Quality of Life in African-American or Caucasian Female Breast Cancer Survivors

NCT00268502
View directory record Official record
Conditions
Breast Cancer, Cancer Survivor, Depression, Fatigue, Sexual Dysfunction, Sleep Disorders, Spiritual Concerns
Interventions
study of socioeconomic and demographic variables, fatigue assessment and management, management of therapy complications, psychosocial assessment and care, quality-of-life assessment
Other · Procedure
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 16, 2015 · Synced Oct 23, 2026, 4:19 PM EDT
Completed Not applicable Interventional

Avon Foundation Program to Improve Quality of Life in Breast Cancer Survivors

NCT00278837
View directory record Official record
Conditions
Breast Cancer
Interventions
Mindfulness based meditation program
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 101 Years · Female only
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 23, 2026, 4:19 PM EDT
Active, not recruiting Not applicable Interventional

Evaluate The Accuracy Of Breast MRI Biopsy In Diagnosing A Complete Tumor Response For Some Women Following Neoadjuvant Chemotherapy For Breast Cancer

NCT03289195
View directory record Official record
Conditions
Breast Cancer
Interventions
MRI Biopsy
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 23, 2026, 4:19 PM EDT
Terminated Phase 1 Interventional

A Study of PY314 in Subjects With Advanced Solid Tumors

NCT04691375
View directory record Official record
Conditions
Advanced Solid Tumor, Gynecologic Cancer, Breast Cancer, Colorectal Cancer, Lung Adenocarcinoma, Renal Cell Carcinoma, Triple Negative Breast Cancer, Hormone Receptor/Growth Factor Receptor-Negative Breast Cancer, Ovarian Cancer
Interventions
PY314, Combination Therapy: PY314 + Pembrolizumab
Drug
Lead sponsor
Ikena Oncology
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
23
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2024 · Synced Oct 23, 2026, 4:19 PM EDT
Completed Phase 1 Interventional

A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies

NCT03538028
View directory record Official record
Conditions
Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer, Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Esophageal Cancer, Hepatocellular Carcinoma, Melanoma (Uveal Melanoma Excluded), Merkel Cell Carcinoma, Mesothelioma, MSI-high Colorectal Cancer, Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Small Cell Lung Cancer (SCLC), Renal Cell Carcinoma (RCC), Triple-negative Breast Cancer, Urothelial Carcinoma, Diffuse Large B-cell Lymphoma
Interventions
INCAGN02385
Biological
Lead sponsor
Incyte Biosciences International Sàrl
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Los Angeles, California • Hackensack, New Jersey • Huntersville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2020 · Synced Oct 23, 2026, 4:19 PM EDT
Completed Phase 1 Interventional

Axillary Reverse Mapping for Invasive Carcinoma of the Breast

NCT00645541
View directory record Official record
Conditions
Breast Cancer
Interventions
Axillary Reverse Mapping
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2012 · Synced Oct 23, 2026, 4:19 PM EDT
Terminated Phase 1Phase 2 Interventional

Vaccination Against High Risk Breast Cancer Using Tumor Derived Heat Shock Protein 70

NCT00027131
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Heat Shock Protein 70-peptide complexes (HSP70)
Biological
Lead sponsor
UConn Health
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 8, 2008 · Synced Oct 23, 2026, 4:19 PM EDT
Completed Phase 2 Interventional

Paclitaxel With or Without PSC 833 in Treating Patients With Metastatic Breast Cancer

NCT00002937
View directory record Official record
Conditions
Breast Cancer
Interventions
paclitaxel, valspodar
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Not listed
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2005
U.S. locations
3
States / cities
Duarte, California • Los Angeles, California • Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 6, 2010 · Synced Oct 23, 2026, 4:19 PM EDT
Completed Not applicable Interventional

Development of a Questionnaire to Evaluate Patient Expectations for Breast Reconstruction in Women With Breast Cancer or Other Conditions

NCT00471601
View directory record Official record
Conditions
Breast Cancer
Interventions
counseling intervention, questionnaire administration, psychosocial assessment and care, quality-of-life assessment
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2023
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Oct 23, 2026, 4:19 PM EDT
Completed Phase 1 Interventional Results available

MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment

NCT01770353
View directory record Official record
Conditions
Solid Tumors, ER/PR Positive Breast Cancer, Triple Negative Breast Cancer, Metastatic Breast Cancer With Active Brain Metastasis
Interventions
Ferumoxytol, MM-398
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
7
States / cities
Scottsdale, Arizona • San Francisco, California • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 23, 2026, 4:19 PM EDT
Completed Phase 2 Interventional Results available

Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant

NCT04224272
View directory record Official record
Conditions
HER2+/HR+ Breast Cancer
Interventions
ZW25 (Zanidatamab), Palbociclib, Fulvestrant
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Santa Monica, California • Nashville, Tennessee • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 23, 2026, 4:19 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)

NCT04439175
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Taselisib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 23, 2026, 4:19 PM EDT
Terminated Phase 1 Interventional Results available

A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.

NCT04209465
View directory record Official record
Conditions
Solid Tumor
Interventions
BDTX-189
Drug
Lead sponsor
Black Diamond Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
24
States / cities
Scottsdale, Arizona • Long Beach, California • Orange, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Oct 23, 2026, 4:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer

NCT01325207
View directory record Official record
Conditions
Breast Cancer
Interventions
Trastuzumab
Radiation
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
8
States / cities
San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Oct 23, 2026, 4:19 PM EDT
Withdrawn No phase listed Observational

Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199

NCT01445275
View directory record Official record
Conditions
Fallopian Tube Carcinoma, Hereditary Breast and Ovarian Cancer Syndrome, Ovarian Carcinoma, Primary Peritoneal Carcinoma
Interventions
Evaluation of Cancer Risk Factors, Medical Chart Review, Study of Socioeconomic and Demographic Variables
Procedure · Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
30 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Oct 23, 2026, 4:19 PM EDT
Recruiting Not applicable Interventional

Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy

NCT05245812
View directory record Official record
Conditions
Breast Cancer, High Risk of Breast Cancer
Interventions
da Vinci SP Surgical System
Device
Lead sponsor
Deborah Farr, MD
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 23, 2026, 4:19 PM EDT
Completed Phase 1 Interventional

Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer

NCT00128622
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Lung Cancer, Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
denileukin diftitox, recombinant fowlpox-CEA(6D)/TRICOM vaccine, therapeutic autologous dendritic cells
Biological
Lead sponsor
H. Kim Lyerly
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 12, 2012 · Synced Oct 23, 2026, 4:19 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer

NCT04331067
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Paclitaxel, Carboplatin, Nivolumab, Cabiralizumab, Tumor biopsy, Bone marrow, Blood draw
Drug · Biological · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 23, 2026, 4:19 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Evaluation of the Bexa Breast Examination

NCT06643767
View directory record Official record
Conditions
Breast Cancer
Interventions
Bexa and focus ultrasound
Device
Lead sponsor
Sure, Inc.
Industry
Eligibility
30 Years to 75 Years · Female only
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Abilene, Texas
Source: ClinicalTrials.gov public record
Updated Oct 18, 2024 · Synced Oct 23, 2026, 4:19 PM EDT